USPTO 2015–2025 USPTO PatentsView US Corporation

Bristol-Myers Squibb Company

USPTO PatentsView assignee record - 1,089 granted patents across 37 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

RSS updates for this company

The verdict

According to USPTO PatentsView, Bristol-myers ranks #413 of 49,997 tracked US assignees by granted-patent volume, with 1,089 patents across 37 technology areas.

#413
of 49,997 US assignees by volume
Top 4%
by Innovation Score (59.3/100)
14.8
avg claims per patent
-20%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R413 · US Corporation #413 · 1,089 grants

GRANTS-LARGE · TOP-DECILE · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-RICH · TYPE-USCORP · VEL-DOWN · BOOK-FULL

  • GRANTS-LARGE 1.1K grants
  • TOP-DECILE #413/49,997
  • PHOTO-FINISH NTN
  • CPC-FOCUS A61P · 37 areas
  • INNOV-PAR 59.3/100
  • CLAIMS-RICH 14.8 claims/avg
  • TYPE-USCORP US Corporation
  • VEL-DOWN -20% vel
  • BOOK-FULL 10/10 fields

Nearest grant-volume peer: NTN Corporation (±2 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Innovation-score neighbourhood around Bristol-myers

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Bristol-myers's Innovation Score is 59.3/100 (top 4% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Where Bristol-myers's grants concentrate

Bristol-Myers Squibb Company is a focused PatentsView assignee: 37 CPC subclasses with 80.7% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2017 (137 grants) versus a trough of 64 in 2023. By volume, Bristol-myers sits between Boston Scientific Neuromodulation Corporation and CA, Inc..

Bristol-myers's three-year grant acceleration

From 2019–2021 to 2022–2024, Bristol-Myers Squibb Company moved from 343 to 245 grants (0.71x the prior three-year total, a multiple, not a CAGR). Among 3,296 tracked assignees with ≥100 grants and ≥20 prior-period grants, that multiple ranks #2,103. See the growth leaderboard.

Who files at Bristol-Myers's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Bristol-Myers holds 1,089 patents at rank #413, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Bristol-Myers

By rank, the assignees closest to #413 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Bristol-Myers's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Bristol-Myers, neither rank-band nor same-CPC leaders (those blocks stay above).

Bristol-myers's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

59 Top 4% higher than 96% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

6080100120140160 20152016201720182019202020212022202320242025 64
USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table
Bristol-Myers Squibb Company patent grants by year, 2015–2025
Year Patents Granted Share of Period
2015 91 8.4%
2016 112 10.3%
2017 137 12.6%
2018 97 8.9%
2019 131 12.0%
2020 106 9.7%
2021 106 9.7%
2022 99 9.1%
2023 64 5.9%
2024 82 7.5%
2025partial year 64 5.9%

Which technologies does Bristol-Myers Squibb Company patent most?

Top 15 of 37 technology areas

Where it ranks

Overall rank by patents

#413

of 49,997 tracked assignees

Innovation Score

59.3 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Bristol-Myers Squibb Company's patent record in context - here's where to go next.

  • Bristol-Myers Squibb Company's lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 80.7% of its portfolio - see every assignee active in that class. Explore A61P
  • Ranked #413 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare Bristol-Myers Squibb Company against Boston Scientific Neuromodulation Corporation, an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 59.3/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.